GlassScriptPhysician profile
William P Knibbe
NPI 1457363673
$163,619.50
in general payments reported to CMS, 2019-2025
20 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $9,062 · 2021: $5,473 · 2022: $31K · 2023: $30K · 2024: $11K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $58K · Consulting Fee: $7,360 · Travel and Lodging: $5,754 · Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,300.00 |
| Consulting Fee | $7,360.00 |
| Travel and Lodging | $5,754.07 |
| Food and Beverage | $1,876.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $43,745.90 | 2019-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $42,940.13 | 2022-2025 | Saphnelo |
| Amgen INC. | $34,467.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $15,844.92 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $15,783.09 | 2019 | |
| Abbvie INC. | $7,479.38 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $2,589.90 | 2021 | |
| Genzyme Corporation | $388.00 | 2020 | |
| Janssen Biotech, INC. | $158.08 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $123.27 | 2019 | |
| Radius Health, INC. | $21.46 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.69 | 2019 | |
| Horizon Therapeutics Plc | $14.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 | |
| Pfizer INC. | $12.78 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.76 | 2022 | |
| Genentech USA, INC. | $10.96 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Knibbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.